The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

A recent selloff of Neurocrine Biosciences stock feels unwarranted and may have created a contrarian buy opportunity. Learn ...

Needham analyst Ami Fadia upgraded Neurocrine (NBIX) to Buy from Hold with a $138 price target The firm cites its positive physician survey on ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

A physician survey for Neurocrine Biosciences Inc's NBIX +1.72% Get Free Report Crenessity suggests "strong uptake across all patient segments," according to Needham. The Neurocrine Biosciences ...

Learn more about whether Neurocrine Biosciences, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ ...

Renal hypoplasia, defined as abnormally small kidneys ... Mayumi M 2002 Renal aplasia is the predominant cause of congenital solitary kidneys. Kidney Int 61: 1840–1844 ...

More women than men are prone to hormonal acne and it is affected by the monthly menstrual cycle, pregnancy and childbirth, ...

During the last three months, 16 analysts shared their evaluations of Neurocrine Biosciences NBIX +1.72% Get Free Report , revealing diverse outlooks from bullish to bearish. The following table ...

Global Newborn Screening Market is projected to grow at a CAGR of ~6–8% from 2022 to 2027. This is likely to be driven by an ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the ...